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Immuno evasionHPV-16 is the major causes of cervical cancer. Persistence of infection is a necessary event for progression of
the infection to cancer. Among other factors, virus persistence is due the viral proteins ﬁghting the immune
response. HPV-16 E5 down-regulates MHC/HLA class I, which is much reduced on the cell surface and
accumulates in the Golgi apparatus in cells expressing E5. This effect is observed also in W12 cells, which
mimic early cervical intraepithelial progression to cervical cancer. The functional effect of MHC I down-
regulation on human CD8 T cells is not known, because of the need for HLA-matched, HPV-speciﬁc T cells
that recognise E5 expressing-cells. Here we employ a heterologous cell/MHC I system which uses mouse
cells expressing both E5 and HLA-A2, and A2-restricted CTLs; we show that the E5-induced reduction of HLA-
A2 has a functional impact by reducing recognition of E5 expressing cells by HPV speciﬁc CD8+ T cells.ed at Institute of Comparative
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Human papillomavirus type 16 (HPV-16) is one of the major
causes of cervical cancer (zur Hausen, 2009). Like most cancers,
cervical carcinogenesis is a multi-step process which starts with viral
infection and requires a number of events to occur for full cell
transformation to take place. One of these events is persistence of viral
infection. Papillomavirus persistence is due to several factors: the
virus life cycle takes place fully within the thickness of the epithelium
and therefore away from dermal immune cells (Stanley et al., 2007),
the virus does not cause cell lysis and therefore no inﬂammatory
response (Stanley et al., 2007), and the viral proteins actively ﬁght the
immune response (O'Brien and Campo, 2002). The E5 protein
contributes to this ﬁght by down-regulating MHC/HLA class I. MHC
class I is much reduced on the cell surface and accumulates in theGolgi apparatus in cells expressing E5 (Ashraﬁ et al., 2005). The arrest
of MHC class I in the Golgi apparatus is due to E5-induced
alkalinisation of the endomembrane compartments (Schapiro et al.,
2000), following E5-16k subunit c interaction, and to the direct
interaction of E5 with the heavy chain of the MHC class I complex
(Ashraﬁ et al., 2006; Cortese et al., 2010). These conclusions have been
reached in cultured HaCaT cells and, in the case of bovine papillomas,
also in vivo (Araibi et al., 2004). However, the functional effect of MHC
I down-regulation on the activity of cytotoxic T lymphocytes (CTLs)
has not been investigated, because HaCaT keratinocytes express
primarily HLA-A3 (A31 B60 B51) and there are no readily available
A3-restricted CTL clones that can be used which could recognise E5
expressing-HaCaT cells. Here we show that also in the cervical cell line
W12 expression of E5 is accompanied by a decreased expression of
HLA, and that E5 expression does reduce recognition by CD8 T cells.
Results and discussion
Expression of HPV-16 E5 is associated with down-regulation of HLA in
the W12 cell system
Previous work on HPV-16 E5 (16-E5) and HLA class I has been
done in HaCaT human keratinocytes. To study E5-HLA interaction in a
more natural setting, we investigated W12 cells, a line of cervical
keratinocytes derived from a cervical intraepithelial grade I (CIN I)
lesion (Stanley et al., 2007). This cell line recapitulates the neoplastic
progression of HPV-16-induced cervical lesions. Early passage W12
138 M.S. Campo et al. / Virology 407 (2010) 137–142cells (W12E) harbour episomal copies of HPV-16, and express all early
viral genes, whereas late passage cells (W12G) harbour integrated
HPV-16 genomes (Jeon et al., 1995) with the loss of the E2-E5 region.
W12 cells are immortal but not transformed and can be grown and
differentiated in three-dimensional organotypic raft cultures, in
which W12E form CIN I-like epithelia and W12G form similarly
structured epithelia but display reduced differentiation and some
invasion (Aasen et al., 2003). InW12E we easily detected E5 mRNA by
RT-PCR (Fig. 1A); on the contrary there was very little or no E5 mRNA
in W12G despite the presence of very similar levels of GAPDH mRNA
in both W12 cell lines (Fig. 1A) in agreement with the integration of
HPV-16 genomes in the E2-E5 region of the viral genome (Jeon et al.,
1995; Alazawi et al., 2002).
The availability of W12 cells with and without E5 expression
prompted us to investigate if the presence of E5 had any effect on the
surface expression of HLA class I.
W12E and W12G cells were analysed by ﬂow cytometry together
with cervical carcinoma cell line CaSki (HPV-16 positive) and
peripheral blood cells (PBMC) as control. As predicted from previous
work, W12E cells showed much less surface HLA class I than W12G
cells (Fig. 1B), which had similar levels of surface HLA as CaSki cells; all
test cells expressed much less surface HLA class I than PBMC (Fig. 1B).
We also analysed surface HLA-A by immunohistochemistry in raft-
cultured W12E and W12G cells, in conditions that mimic the natural
architecture and the biological characteristics of early and late cervical
lesions respectively. The E5-expressingW12E cells showed little or no
HLA class I staining (Fig. 2C) and the staining was predominantly
conﬁned to the cytoplasm (inset) as it is the case in HaCaT cells
expressing 16-E5 (Ashraﬁ et al., 2005). On the contrary, the W12GFig. 1.HPV-16 E5 down-regulates HLA class I inW12 cells. (A) detection of E5mRNA (125 bp
ampliﬁcation of GAPDH mRNA in the samples. (B) Flow cytometry analysis of surface H
Immunohistochemistry of HLA-A in sections of organotypic cultures ofW12E andW12G cells
class I in W12E cells both by ﬂow cytometry and immunohistochemistry.cells (no E5) showed abundant levels of HLA-A on their plasma
membrane and in the cytoplasm (Fig. 2D and inset).
The sensitivity of immunohistochemistry is lower than that of ﬂow
cytometry and this is likely to be the reason why very little HLA class I
is detected in W12E cells by the former technique compared to ﬂow
cytometry. Furthermore ﬂow cytometry has been performed on
undifferentiated cells while immunohistochemistry has been per-
formed on raft-cultured differentiated cells.
In conclusion, also in the natural W12 system which recapitulates
the neoplastic progression of cervical lesions E5 expression is
associated with the down-regulation of surface HLA class I. The
inverse relationship between expression of E5 and of surface MHC I
has already been observed in bovine papillomas (Araibi et al., 2004)
and in a small panel of naturally occurring CIN lesions (Araibi, 2006).
Together with the present results, it appears that E5-associated down-
regulation of surface MHC I in early lesions is a common occurrence.
Introduction of exogenous E5 intoW12E cells or its silencing inW12G
cells should prove a cause-and-effect relationship between presence
of E5 and absence of MHC I.
HPV-16 E5 down-regulates HLA-A2 but not HLA-E in a heterologous
system
To study the recognition of infected cells by CD8 T cells, T cell lines
are needed that are matched to the HLA type of the target cells. HaCaT
keratinocytes express predominantly HLA-A3 (A31 B60 B51) and
W12 cells express predominantly A11 (A11, 24 B8 Bw63) (M Stanley,
personal communication). No CD8 T cell lines are available restricted
to these HLA types and therefore neither HaCaT nor W12 cells can beband) by RT-PCR inW12E cells but not inW12G cells. The top band shows simultaneous
LA class I in W12E and G cells, with CaSki cells and PBMC as controls. (C and D)
respectively. Main panels 5×; inset in C, 20×; inset in D, 40×. Note the reduction of HLA
Fig. 2. HPV-16 E5 and HLA in P815 cells. (A) Quantitative RT-PCR of E5 RNA in two lines of P815 cells carrying pCineo empty vector (P815-pCia and P815-pCib) or pCi-16E5 (P815-16E5a
and P815-16E5b). Note the absence of E5mRNA in P815-pCi cells and the difference in scale between amount of actin (left y axis) and 16E5 (right y axis). (B)Western blotting for HLA-A2
and HLA-E in P815 cells with and without 16E5. Note the absence of HLA-A2 and HLA-E in P815 parental cells and the similar levels of HLA-A and HLA-E whether E5 is expressed or not.
Mouse actinwas the internal control. (C)Western blotting for 16E5 andHLA-A2 in three lines of P815-A2-16E5, one line of P815-16E5, P815 parental cells and human293 cells for control.
Note the absence of 16E5 in the parental cells and of HLA-A2 in P815-16E5 cells.
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induced HLA class I down-regulation on the activity of CD8 T cells.
To overcome this problem, we used P815, a cell line derived from a
mouse mastocytoma (Ellis et al., 1999), which has been successfully
employed in the study of the interaction between BPV E5 and classical
and non-classical bovine MHC class I (Araibi et al., 2006). To assess
whether 16E5 behaves in P815 cells as it does in human cells, we
transfected P815 cells with the heavy chain (HC) of HLA-A2 or the HC
of HLA-E and 16E5, either alone or in combination. HeterologousMHC
heavy chains can interact with mouse β2 microglobulin to form a
functional complex (Ellis et al., 1999).
We derived several cell P815 lines by independent transfections. First
we ascertained that P815 cells expressed 16E5;we detected E5mRNAby
qRT-PCR in two cell lines and E5 protein by western blotting in four
additional cell lines,with orwithoutHLA-A2. The levels of E5mRNAwere
four orders ofmagnitude lower that those of actin (Fig. 2A), in agreement
with E5 expression in HaCaT keratinocytes (Ashraﬁ et al., 2005). The
amount of E5 protein was comparable in the other cell lines (Fig. 2C),
although P815-A2-E5c cells appeared to have somewhat less E5.
Expression of A2 HC and E HC was assessed by western blotting.
The two HC were expressed at approximately the same levels and, as
in HaCaT keratinocytes, E5 did not affect their levels (Fig. 2B and C).
Next we assessed the effect of 16E5 on HLA-A2 or HLA-E surface
expression by ﬂow cytometry and immunoﬂuorescence. It was clear
that 16-E5 noticeably down-regulated the surface expression of HLA-
A2, but not that of HLA-E (Fig. 3), conﬁrming that 16E5 does not affect
the transport of HLA-E to the cell surface (Ashraﬁ et al., 2005).
Interestingly, in P815-16E5 cells the expression of surfacemouseMHC
I was also down-regulated compared to P815 parental cells (results
not shown), corroborating previous results that both BPV and HPV E5proteins are capable of interfering with the transport of MHC I to the
cell surface independently of cell species (Ashraﬁ et al., 2005, 2002;
Marchetti et al., 2002, 2009).
By immunoﬂuorescence, both HLA-A2 and HLA-E were detected in
the Golgi apparatus, as judged by the orange colour (merge of red
Golgi and green HLA) and on the cell surface (green HLA) in the cells
not expressing E5 (Fig. 3). On the contrary, HLA-A was detected only
in the Golgi apparatus in cells expressing E5, while the location of
HLA-E was not affected (Fig. 3). These results agree completely with
those obtained in HaCaT keratinocytes.
HPV-16 E5 reduces recognition by CD8 T cells
Having established that 16E5 behaves in P815 cells as it
does in human keratinocytes, we conducted CD8+ T cell activation
assays, in which the read-out for functional activity was the
production of γ-interferon (γIFN) (Thomas et al., 2008). This is
more stringent than measuring cytotoxic function because more
peptide:HLA complexes are required to induce cytokine release
when compared to cytotoxicity (Valitutti et al., 1996). We used the
well-established CD8+ T cell clone 7E7 isolated from a cervical cancer
patient which recognises a peptide epitope from HPV16 E629–38
(TIHDIILECV) presented by HLA-A2 (Evans et al., 2001). This T
cell clone was co-cultured with P815 parental cells, P815-A2 and
P815-A2-E5 cells after they had been loaded with increasing amounts
of the E629–38 peptide. Consistent results were obtained in several
repeat experiments; namely that the parental cells P815 (HLA-A2
negative) did not induce any γIFN production by 7E7 T cells, whereas
P815-A2 cells did elicit γIFN production in a peptide dose-dependent
manner (Fig. 4). Themagnitude of the latter responsewas comparable
Fig. 3.HPV-16 E5 down-regulates HLA-A2 but not HLA-E in P815 cells. FC: ﬂow cytometry for surface HLA-A and HLA-E with andwithout 16E5. 16E5 decreases the amount of surface
HLA-A2 but not surface HLA-E. The dashed vertical line indicates the mean forward ﬂuorescence. IF: immunoﬂuorescence; the Golgi apparatus in P815 cells was stained red with
BODIPY-TR-ceramide and HLA-A2 and HLA-E were stained green by FITC-conjugated secondary antibodies. HLA is detected on the cell surface in P815-A2, P815-E and P815-E-16E5
cells but not in P815-A2-16E5 cells. Note that the IF panel showing P815-E-16E5 cells is a composite of two ﬁelds, put together for ease of comparison with the other panels.
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not shown). However a clear reduction in γIFN production by 7E7 was
observed for the P815-A2-E5 cells at every dose of peptide tested
(Fig. 4). This ranged from 50% to 70% of the maximum response
(highest dose of peptide with P815-A2) to no response at the lowest
dose of peptide in repeat experiments. The reduction in γIFN
production correlatedwith the decrease in surface HLA-A2 expression
in the P815-A2-E5 cells (Fig. 3).
We conclude that E5 expression has an impact on functional
recognition by an HPV speciﬁc T cell clone, by reducing the number of
HLA molecules available to present HPV peptide epitopes. In this
respect E5 is similar to many other viral proteins which down-
regulate HLA/MHC I, reduce antigen presentation and preventFig. 4. HPV16 E5 reduces recognition by CD8+ T cells. Parental P815, P815-A2 or P815-
A2-E5 cells were loaded with varying doses of HPV16 E629–38 peptide before co-culture
with the HPV16 E629–38 speciﬁc T cell clone 7E7 for 20 hours. Supernatants from
duplicate culture wells were assayed for γIFN by ELISA. Note the poor response of 7E7 T
cells to P815-A2-E5 cells. Note too the lack of γIFN production by 7E7 in the absence of
peptide, showing the speciﬁcity of the assay.recognition and killing by CTL (reviewed in Lilley and Ploegh, 2005).
In humans, E5 could play an important role in the establishment and
persistence of HPV infection by allowing the infected cells to escape
host immunosurveillance. The persistent lesions arising from this
immune evasion would be at greater risk of undergoing additional
oncogenic events which would trigger malignant transformation.
Attempts to treat malignant disease caused by oncogenic papilloma-
viruses through use of therapeutic vaccines have met with limited
success. This may be explained in part by the powerful suppressive
mechanisms exerted both locally and systemically in advanced
cancer. However it is clear from animal models of papillomavirus
infection that inﬁltrating T cells are involved in regression of
papillomavirus lesions (Knowles et al., 1996; Nicholls et al., 2001;
Selvakumar et al., 1997). Furthermore, a recent trial using a synthetic
peptide vaccine in pre-malignant disease (VIN3) demonstrated
clinical efﬁcacy in 47% of vaccinated patients, with these clinical
responses correlating with boosted T cell immunity (Kenter et al.,
2009). This suggests that strong T cell responses against oncogenic
HPVs would be beneﬁcial in early disease, when the immune system
has not been suppressed by cancer cells. Further research on E5 is
warranted, particularly in developingmethods to speciﬁcally block E5
expression. It may be possible to combine these with vaccination
approaches to maximise the efﬁcacy of any induced HPV speciﬁc T cell
responses and thereby prevent the development of malignant disease.Materials and methods
Plasmids
pCi-16E5 has the HPV-16 E5 (16E5) ORF tagged with the HA
epitope at its 5’ end cloned in pCineo (Promega) in which E5 is
expressed under the control of the immediate early (IE) promoter of
141M.S. Campo et al. / Virology 407 (2010) 137–142human cytomegalovirus (hCMV) (Ashraﬁ et al., 2006). The plasmid
confers G418 resistance.
The HLA-A2 and HLA-E coding sequences were excised from
pAL356HLA-A2 and pAL269HLA-E (Tomasec et al., 2000; Youde et al.,
2005) and cloned into pcDNA6 under the transcriptional control of
hCMV IE promoter to generate pcDNA6/HLA-A2 and pcDNA6/HLA-E.
Both plasmids confer blasticidin resistance.
Antibodies
Monoclonal antibody (mAb) W6/32 (Serotec) is raised against
HLA-A, B and C; mAb DT9 (kind gift of Dr V. Braud, Sophia Antipolis,
France) is raised against HLA-E. mAb HC10 (Cancer Research UK) is
raised against HLA-class I heavy chain (HC) and mAb MEM-E/02




W12 is a line of human cervical keratinocytes explanted from a CIN I
lesion (Stanley et al., 2007). W12E is an early passage clone (p17) that
harbours episomal copies of HPV-16,W12G is a late passage clone (p25)
with integrated HPV-16 genomes (Jeon et al., 1995). W12E and G cells
were co-cultured with 4 μg/ml mitomycin C-treated J2 3T3 ﬁbroblasts
at a ratio of 1:5 where 2×105 W12 cells were added per 10 cm culture
dish. Cells were grown for 10 days in DMEM, 10% foetal calf serum,
2 mM glutamine, cholera toxin (8.4 ng/ml), hydrocortisone (0.4 ng/
ml), and epidermal growth factor (5 ng/ml) (McPhillips et al., 2004).
P815
P815 is a line of mouse mastocytoma cells (ATCC). P815 cells were
grown in suspension in RPMI medium supplemented with 10% FCS
(Invitrogen) and penicillin/streptomycin. Cells were maintained at
37 °C 5% CO2. Stably transfected cellsweremaintained as parental cells
with the addition of selective antibiotics where appropriate: G418
(Invitrogen) at 500 μg/ml in case of E5 expression plasmids, and/or
blasticidin (InvivoGen) at 10 μg/ml in case of HLA-A2 and HLA-E.
CTL clone 7E7
The CTL clone 7E7 was isolated from a cervical cancer patient; it
recognises a peptide epitope from HPV16 E629–38 (TIHDIILECV)
presented by HLA-A2 (Evans et al., 2001). The cells were grown as
previously described (Evans et al., 2001). Brieﬂy, 1×106 7E7 CTL were
cultured in tissue culture ﬂasks containing 20×106 irradiated
allogeneic peripheral blood mononuclear cells, rIL2 (20 IU/ml),
phytohaemaggultin (Murex, 1 μg/ml) in RPMI1640 media with 10%
human AB serum. After 7 days, the CTL were transferred to 24 well
plates, and culture continued in fresh media supplemented with
100 IU/ml rIL2 for up to 14 days.
Organotypic raft cultures
W12E and W12G cells were grown in organotypic raft cultures
basically as described before (Aasen et al., 2003). Brieﬂy, 2.5×105 cells
were seeded on a contracted lattice of collagen type I containing
primary human epidermal ﬁbroblasts (3×105 cells perml collagen) in
3:1 DMEM: Ham's F12 medium containing 10% FCS, 0.1 mg/ml L-
glutamine, 0.4 ng/ml hydrocortisone, 10 ng/ml cholera toxin, 5 μg/ml
insulin, 180 nM adenine, 5 μg/ml transferrin and 5 ng/ml EGF. The
lattice was lifted to the air–liquid interface after 3 days and ﬁxed in 4%
(v/v) formaldehyde after 12–14 days of stratiﬁcation. Sections were
parafﬁn embedded and processed for routine H&E.
Transfections
One x106 P815 cells were transfected using an Amaxa nucleofector
(Amaxa GmBH) according to the manufacturer's instructions. Cellswere allowed to grow for 48 hrs before the addition of selective
media. Selection was carried out for approximately three weeks.
Several independent transfections were carried out and polyclonal
lines derived from them.
RT-PCR
RNAwas prepared fromW12 cells using Trizol reagent (Invitrogen)
according to the manufacturer's instructions. RNA was reverse
transcribed into cDNA using Superscript III (Invitrogen) and PCR-
ampliﬁed using E5 forward primer 5'-ATGACAAATCTTGATACTGCA-3'
and E5 reverse primer 5'-AATGATGTGTATGTAGACACAG-3' and GAPDH
forward primer 5'-TCCACCACCCTGTTGCTGTA-3' and GAPDH reverse
primer 5'-ACCACAGTCCATGCCATCAC-3' with Taq DNA polymerase
(Invitrogen). RT-PCR reactions were fractionated on acrylamide gels.
Quantitative RT-PCR
The expression of E5 in P815 cells was analysed by quantitative RT-
PCR (qRT-PCR) using primers/probes for 16E5 and for mouse actin as
described previously (Araibi et al., 2006; Ashraﬁ et al., 2005).
Western blotting
E5 expression in P815 cells was also analysed by western blotting
using mAb HA11 (Sigma) against the HA epitope. The expression of
HLA-A2 and HLA-E was analysed using mAb HC10 and MEM-E/02
respectively.
Flow cytometry
Flow cytometry analysis of P815 cells was basically carried out as
described in (Araibi et al., 2006), with the difference that mAbW6/32
(1:100) was used for the detection of HLA-A2 andmAb DT9 (1:10) for
the detection of HLA-E. After the addition of anti-mouse FITC-
conjugated IgG (1:100; Sigma) at 4 °C for 30 min in the dark, the
cells were washed and examined in a Beckman Coulter EPICS Elite
analyser equipped with an ion argon laser with 15 mV of excitation at
488 nm. The data were analysed using Expo 2 software.
Immunoﬂuorescence
Immunoﬂuorescence analysis of P815 cells was carried out as
described in (Araibi et al., 2006). Brieﬂy, the Golgi apparatus was
visualised with 1:1000 dilution of BODIPY Ceramide Texas Red (TR)
(in 2.5% HEPES in serum-free medium) for 30 min at 4 °C. After
removal of BODIPY Ceramide, cells were incubated in 2.5% HEPES in
serum-free RPMI 1640 medium for 30 min at 37 °C and then
incubated with W6/32 for HLA-A2 or DT9 for HLA-E. After the
addition of anti-mouse FITC-conjugated IgG secondary antibody, cells
were washed three times and the coverslips were mounted onto
slides using Citiﬂuor. Images were captured using a Leica TCS SP2 true
confocal scanner microscope (Leica Microsystems, Heidelberg,
Germany) at a wavelength of 488 nm (MHC class I: FITC) or 543 nm
(Golgi apparatus: Texas Red). The merge between the ﬂuorescent
signals was achieved using the accompanying software.
Immunohistochemistry
This procedure was performed by the Pathological Services of
the Institute of Comparative Medicine. Brieﬂy, sections were de-
parafﬁnised, heated in a pressure cooker for antigen retrieval for HLA
detection. Endogenous peroxidase was blocked using peroxidase block
(Envision Kit DakoCytomation) and then the sectionswerewashed ﬁrst
with Tris/Tween then twicewithwater.mAbHC10 (1:2000)was added
and after washing with Tris/Tween the secondary antibody conjugated
with horseradish peroxidase was applied; dual anti-mouse/rabbit
(Dako) was used for all antibodies. Sections were washed as above
and DAB was added (Envision Kit, DakoCytomation). Then sections
were counter-stained with haematoxylin, de-hydrated and mounted.
The stained sectionswere analysed using a Zeiss Axioskop 2microscope
and images were digitally captured with the accompanying camera and
142 M.S. Campo et al. / Virology 407 (2010) 137–142software KS300 version 3. Absence of primary antibodies resulted in no
staining in all cases (not shown).
γIFN release assays with P815 cells
P815 parental cells, P815-A2 and P815-A2-E5 cells were resus-
pended in 1 m aliquots (106/ml) of serum free RPMI1640media in the
presence of varying doses of E629–38 peptide (Severn Biotech). After 2
hours incubation at 37°C, the cells were washed three times in serum-
free RMPI1640 before resuspending in tissue culture media
(RPMI1640+10% human AB serum). The peptide loaded P815
parental, P815-A2 and P815-A2-E5 transfectant cells (5×104 cells/
well) were co-incubated with 7E7 T cells (105 cells/well) in 48 well
plates for 18–20 h. γIFN release by 7E7 T cells was measured using an
γIFN ELISA kit (Mabtech, Nacka Strand, Sweden) as previously
described (Thomas et al., 2008).
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